• JPM, Day 3: CureVac partner Bayer says not to discount its vaccine efforts, CROs better prepped for new wave and more

    6 days ago - By Fierce Biotech

    JPM, Day 3: CureVac partner Bayer says not to discount its vaccine efforts, CROs better prepped for new wave and more badams
    Wed, 01/13/2021 - 09:40
    Read more ...

     

  • JPM: CureVac's new pharma partner Bayer says its COVID-19 vaccine not just an also-ran

    6 days ago - By Fierce Biotech

    JPM: CureVac's new pharma partner Bayer says its COVID-19 vaccine not just an also-ran badams
    Wed, 01/13/2021 - 09:16
    Read more ...

     

  • A COVID-19 treatment candidate that fuses tiny antibodies from llamas and alpacas shows promise

    6 days ago - By Fierce Biotech

    A COVID-19 treatment candidate that fuses tiny antibodies from llamas and alpacas shows promise aliu
    Wed, 01/13/2021 - 07:10
    Read more ...

     

  • Celltrion's COVID-19 antibody improves outcomes in phase 2

    6 days ago - By Fierce Biotech

    Celltrion's COVID-19 antibody improves outcomes in phase 2 ntaylor
    Wed, 01/13/2021 - 06:25
    Read more ...

     

  • JPM: PPD C-suite: CROs 'better prepared' as COVID-19 surges, sees pandemic trials a long-term opportunity

    6 days ago - By Fierce Biotech

    JPM: PPD C-suite: CROs 'better prepared' as COVID-19 surges, sees pandemic trials a long-term opportunity badams
    Wed, 01/13/2021 - 04:39
    Read more ...